Hot News
New Delhi: The World Health Organization (WHO) has given its endorsement to a cost-effective and highly efficient malaria vaccine developed through collaboration between the Pune-based Serum Institute of India (SII) …
WHO approves world’s 2nd malaria vaccine; cheaper & easier to produce Read More
RNS: The prices of Covid vaccine, COVISHIELD (Serum Institute) and COVAXIN (Bharat Biotech) have been slashed for private hospitals. The price of the Covishield vaccine has been reduced from 600 …
Covishield, Covaxin price cuts to Rs 225 per dose for private hospitals Read More
by Ashis Sinha Two more vaccinations and one antiviral medicine have received emergency use authorization from the Government of India to help fight the continuing Covid-19 outbreak, informed health minister …
India approves 2 more Vaccines, 1 Pill to fight against COVID Read More
RNS I New Delhi: Covid-19 deterrent vaccine for children of age more than three years will be available in the country within next six months. Adar Poonawalla, CEO Serum Institute …
COVID-19 Vaccine for children 3+ in next 6 months : CEO SII Read More RNS: Covovax, another COVID-19 vaccine, being manufactured by Serum Institute of India, will be launched in October for adults and for children by the first quarter of 2022, said Adar …
COVID jab for kids by first quarter of 2022: Poonawalla Read More
RNS: The Serum Institute of India (SII) a Pune-based Pharma Company is on move to produce Novavax’s COVID-19 vaccine in India. The SII has carried out preparatory work on the …
Serum Institute to begin production of Covovax— Novavax’s COVID-19 vaccine in India Read More
RNS: The government has increased the intervals between two doses of Covishield to 12 to 16 weeks from the existing 6 to 8 weeks on Thursday. This is the second …
Covishield 2nd dose interval increases to 12-16 weeks Read More
RNS: An expert panel on Tuesday recommended Covaxin (COVID-19 vaccine) for phase-2 and phase-3 clinical trial on younger population aged between 2 to 18 years, official sources said. The trial …
Covaxin gets approval for phase 2, 3 trials on 2-18 year-olds Read More
# The government of India had paid an advance of over Rs 2,500 crore to Serum Institute of India (for Covishield) and Bharat Biotech (Covaxin) for supply of 16 crore …
Covishield shortage will last till July: Adar Poonawalla Read More RNS: Adar Poonawalla, CEO of the Serum Institute of India (SII), the largest producer of vaccines globally, said in a tweet that “he will return to India from London in a …
SII CEO flies to London, will back to India soon Read More